Month: September 2024

Release – SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2024 Results

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SLQT09/13/2024

Download(opens in new window)

Fourth Quarter of Fiscal Year 2024 – Consolidated Earnings Highlights

  • Revenue of $307.2 million
  • Net loss of $31.0 million
  • Adjusted EBITDA* of $14.4 million

Fiscal Year 2025 Guidance Ranges:

  • Revenue expected in a range of $1.4 billion to $1.5 billion
  • Net loss expected in a range of $42 million to $6 million
  • Adjusted EBITDA* expected in a range of $90 million to $120 million

Fourth Quarter Fiscal Year 2024 – Segment Highlights

Senior

  • Revenue of $114.1 million
  • Adjusted EBITDA* of $27.9 million
  • Approved Medicare Advantage policies of 107,272

Healthcare Services

  • Revenue of $145.2 million
  • Adjusted EBITDA* of $0.9 million
  • Approximately 82,000 SelectRx members

Life

  • Revenue of $42.1 million
  • Adjusted EBITDA* of $7.2 million

Auto & Home

  • Revenue of $7.6 million
  • Adjusted EBITDA* of $2.5 million

OVERLAND PARK, Kan.–(BUSINESS WIRE)– SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the fourth quarter of fiscal year 2024 of $307.2 million compared to consolidated revenue for the fourth quarter of fiscal year 2023 of $221.8 million. Consolidated net loss for the fourth quarter of fiscal year 2024 was $31.0 million compared to consolidated net loss for the fourth quarter of fiscal year 2023 of $47.8 million. Finally, consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2024 was $14.4 million compared to consolidated Adjusted EBITDA* for the fourth quarter of fiscal year 2023 of $(5.8) million.

Consolidated revenue for the fiscal year ended June 30, 2024, was $1.3 billion compared to consolidated revenue for the fiscal year ended June 30, 2023, of $1.0 billion. Consolidated net loss for the fiscal year ended June 30, 2024, was $34.1 million compared to consolidated net loss for the fiscal year ended June 30, 2023, of $58.5 million. Finally, consolidated Adjusted EBITDA* for the fiscal year ended June 30, 2024, was $117.0 million compared to consolidated Adjusted EBITDA* of $74.3 million for the fiscal year ended June 30, 2023.

SelectQuote Chief Executive Officer, Tim Danker, commented, “2024 was another successful and strong year for SelectQuote across both Senior Medicare Advantage distribution and our Healthcare Services business, driven by SelectRx. On a consolidated basis our fiscal year revenue and Adjusted EBITDA outperformed the midpoint of our original forecast by 17% and 26%, respectively. This marks the 10th consecutive quarter of outperformance versus our internal expectations, reaffirming our strategy to prioritize profitability and cash efficiency over volume growth. Revenue growth was driven primarily by 68% growth in SelectRx members and increasing utilization. Our profitability was driven by another strong year of execution in Senior, which achieved a 25% Adjusted EBITDA margin, similar to a very strong fiscal 2023. Additionally, our Healthcare Services segment achieved its 5th straight quarter of profitability ending the year with Adjusted EBITDA of $7.8 million, which compares to an Adjusted EBITDA loss of $22.8 million in fiscal 2023. Lastly, SelectQuote has signed a non-binding letter of intent to complete an initial commissions receivable securitization of approximately $100 million with certain of our term lenders. Provided this deal closes in the coming weeks, we believe this will be an important first step in our strategic imperative to optimizing our balance sheet capacity, lowering our funding costs, and extending our debt maturities.”

Mr. Danker continued, “SelectQuote’s unique healthcare information platform remains best positioned as a value creation conduit, efficiently connecting a large and growing population of Americans in need of coverage and care with the best providers, based on each of their distinct personal needs.”

Segment Results

We currently report on four segments: 1) Senior, 2) Healthcare Services, 3) Life, and 4) Auto & Home. The performance measures of the segments include total revenue and Adjusted EBITDA*. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is our segment profit measure to evaluate the operating performance of our business. We define Adjusted EBITDA as net loss plus: (i) interest expense, net; (ii) benefit for income taxes; (iii) depreciation and amortization; (iv) share-based compensation; (v) goodwill, long-lived asset, and intangible assets impairments; (vi) transaction costs; (vii) loss on disposal of property, equipment and software, net; and (viii) other non-recurring expenses and income. Adjusted EBITDA Margin is calculated as Adjusted EBITDA divided by revenue.

Senior

Financial Results

Operating Metrics

Submitted Policies

Approved Policies

Lifetime Value of Commissions per Approved Policy

Healthcare Services

Financial Results

Operating Metrics

Members

Combined Senior and Healthcare Services – Consumer Per Unit Economics

The opportunity to leverage our existing database and distribution model to improve access to healthcare services for our consumers has created a need for us to review our key metrics related to our per unit economics. As we think about the revenue and expenses for Healthcare Services, we note that they are derived from the marketing acquisition costs associated with the sale of an MA or MS policy, some of which costs are allocated directly to Healthcare Services, and therefore determined that our per unit economics measure should include components from both Senior and Healthcare Services. See details of revenue and expense items included in the calculation below.

Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents’ core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company’s reassessment of its cohorts’ transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost (“CAC”) multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

Total revenue per MA/MS policy increased 25% for the twelve months ended June 30, 2024, compared to the twelve months ended June 30, 2023, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 25% for the twelve months ended June 30, 2024, compared to the twelve months ended June 30, 2023, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business, offset by a decrease in our marketing and advertising costs.

Life

Financial Results

The following table provides the financial results for the Life segment for the periods presented:

Operating Metrics

Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

Auto & Home

Financial Results

Operating Metrics

Auto & Home premium represents the total premium value of all new policies that were approved by our insurance carrier partners during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Auto & Home segment.

Earnings Conference Call

SelectQuote, Inc. will host a conference call with the investment community on September 13, 2024, beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://www.netroadshow.com/events/login?show=7297aa9f&confId=70516 . After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx .

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies. We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss). We define Adjusted EBITDA Margin as Adjusted EBITDA divided by revenue. The most directly comparable GAAP measure is net income margin. We monitor and have presented in this release Adjusted EBITDA and Adjusted EBITDA Margin because they are key measures used by our management and Board of Directors to understand and evaluate our operating performance, to establish budgets, and to develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. We believe that these non-GAAP financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude in the calculations of these non-GAAP financial measures. Accordingly, we believe that these financial measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects. Reconciliations of net income (loss) to Adjusted EBITDA are presented below beginning on page 13.

Forward Looking Statements

This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: impacts of the COVID-19 pandemic and any other significant public health events; our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; our ability to regain and maintain compliance with NYSE listing standards; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in the most recent Annual Report on Form 10-K (the “Annual Report”) and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) provides solutions that help consumers protect their most valuable assets: their families, health, and property. The company pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads.

With an ecosystem offering high touchpoints for consumers across Insurance, Medicare, Pharmacy, and Value-Based Care, the company now has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with best-in-class healthcare services that fit each member’s unique healthcare needs. The platform improves health outcomes and lowers healthcare costs through proactive engagement and access to high-value healthcare solutions.

View The Full Release Here.

Investor Relations:
Sloan Bohlen
877-678-4083
investorrelations@selectquote.com

Media:
Matt Gunter
913-286-4931
matt.gunter@selectquote.com

Source: SelectQuote, Inc.

Stocks Rise and Gold Hits Record High Amid Expectations for Larger Fed Rate Cut

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Investors now expect a potential 50-basis point Fed rate cut next week, up from prior expectations of a 25-basis point reduction.
– Gold reaches a record high, supported by dollar weakness and looming rate cuts.
– Crude oil continues its rally as hurricane-related supply concerns rise.

U.S. stocks opened higher on Friday, and gold surged to a record high, as investors grew increasingly optimistic about the Federal Reserve’s potential for a 50-basis point interest rate cut next week. Earlier, market expectations had pointed to a smaller 25-basis point reduction, but reports from The Financial Times and The Wall Street Journal suggested the decision might be more evenly split than previously thought. These reports have caused a sharp change in market sentiment, driving gains in multiple sectors.

In early trading, all three major U.S. stock indexes saw positive movements, with the Dow Jones Industrial Average up 0.36%, the S&P 500 gaining 0.26%, and the Nasdaq Composite climbing 0.16%. Investors are now positioning themselves for potential rate cuts, encouraged further by influential voices like former New York Federal Reserve President Bill Dudley, who said during a forum in Singapore that “there’s a strong case for 50,” referencing a more significant rate cut.

Beyond the scope of next week’s interest rate decision, market participants are also closely watching the Federal Reserve’s forward guidance, particularly its dot plot projections and the statements from Chair Jerome Powell at the post-meeting press conference. According to analysts at TD Securities, the decision could be more contentious than anticipated, with the Fed expected to maintain a broadly dovish tone moving forward.

Gold Prices Surge on Dollar Weakness

Gold prices soared to a record high of $2,579.61 per ounce, marking its strongest weekly gain since mid-August. Investors flocked to the safe-haven asset, which benefits from a weakening U.S. dollar and expectations of further rate cuts. Gold’s appeal tends to rise when interest rates are cut, as lower rates reduce the opportunity cost of holding non-yielding assets like gold.

The U.S. dollar saw significant declines, dropping as much as 1% against the yen to 140.36, its weakest level since December 2023. The dollar index, which tracks the currency against major global counterparts, fell to a one-week low at 101.00. The Japanese yen’s strength was also bolstered by hawkish comments from Bank of Japan officials, signaling potential policy tightening in Japan.

Treasury Yields and Crude Oil React

In the bond market, U.S. Treasury prices rose, causing yields to fall. The benchmark 10-year Treasury yield dropped 2.1 basis points to 3.659%, while rate-sensitive two-year yields fell 6.8 basis points to 3.5803%. The rally in Treasuries indicates growing market confidence in further rate cuts by the Federal Reserve.

Crude oil prices continued to climb, with prices reaching $69.51 per barrel as producers assess the impact of Hurricane Francine, which tore through the Gulf of Mexico. The storm has raised concerns over potential disruptions in oil production, further supporting the upward trend in oil prices.

Market Outlook

As the week progresses, investors will be closely monitoring the Fed’s rate decision and the accompanying guidance on future monetary policy. With inflation easing and economic indicators pointing to slower growth, the market anticipates that further rate cuts may follow throughout the rest of the year. This sentiment has helped lift stocks, gold, and oil, creating a more bullish outlook for the markets in the short term.

Biotech IPOs Raise $700 Million, Led by MBX Biosciences, Bicara Therapeutics, and Zenas BioPharma

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– MBX Biosciences raised $163.2 million, focusing on metabolic and endocrine disorders.
– Bicara Therapeutics and Zenas BioPharma raised $315M and $225M, respectively.
– These IPOs reflect renewed investor interest in biotech amid a sluggish broader market.

In a significant boost to the biotech IPO market, three emerging biotech companies—MBX Biosciences, Bicara Therapeutics, and Zenas BioPharma—collectively raised over $700 million through initial public offerings (IPOs). This surge in biotech IPOs, after a quiet summer, underscores the sector’s ability to attract investor attention despite broader market challenges.

MBX Biosciences successfully raised $163.2 million by pricing 10.2 million shares at $16 each, the high end of its expected range. MBX is developing peptide-based therapies for treating metabolic and endocrine disorders, including its lead candidate, MBX 2109, which targets chronic hypoparathyroidism. The company is also developing a preclinical therapy, MBX 4291, aimed at treating obesity by mimicking the effects of gut hormones GLP-1 and GIP. These advances in weight-loss therapies have garnered significant investor interest, especially as obesity treatments like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy continue to show potential for reducing risks such as stroke and heart attacks.

Another notable IPO, Bicara Therapeutics, raised $315 million, positioning itself as the third-largest biotech IPO of the year. Bicara is focused on developing bifunctional antibody drugs for treating cancers, including head and neck cancers. With plans to launch a late-stage trial alongside Merck’s Keytruda, Bicara is well-positioned to explore treatments for other solid tumors as well.

Zenas BioPharma raised $225 million through its IPO and is gaining traction in the immunology space. Zenas is developing a dual-targeting antibody currently in Phase 3 testing for treating IgG4-related diseases and anemia. With potential applications for multiple sclerosis and lupus, the company is riding a wave of enthusiasm for immune therapies, contributing to its successful public offering.

These IPOs reflect a growing interest in later-stage biotech companies, with all three firms advancing drugs already in human testing. The renewed confidence in the sector could also signal more biotech IPOs on the horizon, particularly as companies look to capitalize on robust investor demand for novel therapies in metabolic diseases, cancer, and immunology.

In a market that has been challenging for biotech firms, these successful IPOs highlight the resilience of companies with strong pipelines and innovative approaches to medical treatment. With MBX Biosciences set to trade under the symbol “MBX” on the Nasdaq Global Select Market, investors are closely watching the sector, hopeful that this uptick in activity is a sign of better things to come for biotech in 2025.

Take a moment to take a look at Noble Capital Markets Senior Research Analyst Robert LeBoyer’s coverage list of emerging growth biotechnology companies.

Noble Capital Markets Emerging Growth Basic Industries Virtual Conference Presenting Companies

Posted on by cpatches
Investor / Attendee Registration
View the Conference eBook

Anterix (ATEX)
Watch the Presentation
AZZ, Inc. (AZZ)
Watch the Presentation
Comstock (LODE)
Watch the Presentation
Dryden Gold (DRY:CA)
Watch the Presentation
Eurodry (EDRY)
Watch the Presentation
Euroseas (ESEA)
Watch the Presentation
Giga Metals (GIGGF)
Watch the Presentation
Goliath Resources (GOTRF)
Watch the Presentation
Granite Ridge Resources (GRNT)
Watch the Presentation
Great Lakes Dredge & Dock Corporation (GLDD)
Watch the Presentation
Greenfire Resources (GFR)
Watch the Presentation
Maple Gold Mines (MGMLF)
Watch the Presentation
Mistras Group (MG)
Watch the Presentation
Norsk Titanium (NORSF)
Watch the Presentation
Southern Silver Exploration (SSVFF)
Watch the Presentation
Twin Disc Incorporated (TWIN)
Watch the Presentation
United States Antimony Corporation (UAMY)
Watch the Presentation
V2X (VVX)
Watch the Presentation

Wall Street Rises as August PPI Data Points to Modest Rate Cut by the Fed

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Wall Street’s main indexes rose after August producer price data reinforced expectations of a 25-basis point rate cut.
– Moderna shares tumbled following a weak revenue forecast, while communication services led sector gains.
– Gold miners surged, benefiting from record-high gold prices.

Wall Street’s major indexes climbed Thursday, buoyed by producer price index (PPI) data that met expectations, pointing to a smaller interest rate cut by the Federal Reserve. The PPI for August showed a 0.2% increase, slightly higher than the anticipated 0.1%, while core prices (excluding volatile food and energy) rose 0.3%, indicating that inflation pressures are continuing to ease but remain a concern. This data has solidified investor expectations of a 25-basis point rate cut at the Fed’s September 17-18 meeting, as opposed to a more aggressive 50-basis point cut.

The stock market responded positively, with the Dow Jones Industrial Average up 0.40%, the S&P 500 gaining 0.70%, and the Nasdaq Composite rising 1.04%. The report also showed initial claims for unemployment benefits at 230,000, aligning with estimates and signaling that the labor market is cooling but remains stable.

Investors remain optimistic despite concerns over inflation, with some bargain hunting occurring in the more economically sensitive small-cap Russell 2000 index, which outperformed with a 1.4% rise. According to Chuck Carlson, CEO of Horizon Investment Services, “There’s a willingness among investors to buy on declines,” highlighting growing confidence in a more controlled inflation environment.

However, Moderna faced significant losses, dropping over 11.5% after issuing a disappointing revenue forecast for fiscal year 2025, citing a lower-than-expected demand for vaccines. This dragged down the healthcare sector, although the rest of the market showed strength in communication services and gold mining stocks. Shares of Warner Bros. Discovery surged nearly 9% following news of a strategic partnership with Charter Communications, further boosting investor sentiment in the media and communications space.

The gold mining sector was another bright spot in the market, with spot gold prices reaching new highs, driving up the Arca Gold BUGS index by 6.3%. Investors flocked to gold as a safe-haven asset amid global economic uncertainties, propelling mining stocks like Newmont Corporation and Barrick Gold.

The backdrop of cooling inflation is encouraging for investors who anticipate that the Fed will begin a more dovish monetary policy cycle. A quarter-point rate cut would mark the first reduction since March 2020, when the pandemic triggered rapid monetary easing. With the U.S. central bank likely to cut rates next week, expectations for further rate reductions in 2024 are growing, depending on how inflation and labor market data evolve.

Looking ahead, investors will continue to monitor economic indicators closely, especially as concerns about the health of the U.S. economy persist. While inflation appears to be retreating, the possibility of a broader economic slowdown could influence market sentiment in the coming months. For now, the stock market is riding high on the belief that the Federal Reserve’s actions will continue to support growth while taming inflation.

Release – Kratos Announces Immediate Availability of TDI’s Four Classes of Low-Cost Turbojet Engines

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on KTOS

High-Performance, USA-Made Engines Now Available with No Lead Time

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in Defense, National Security and Global Markets, today announced that Technical Directions, Inc. (TDI), a business unit within Kratos’ Unmanned Systems Division, now offers four classes of its low-cost, high-performance turbojet engines with immediate availability. These engines, ranging from 30 to 200 pounds of thrust, are designed and manufactured in the United States at TDI’s facility in Oxford, Michigan, with all parts and components sourced from U.S. companies.

Known for their compact size and reliable performance, TDI’s turbojets are ideal for use in cruise missiles, loitering munitions systems, and other critical defense systems. Kratos’ commitment to affordability and innovation is at the forefront of this announcement, ensuring that customers can quickly access these engines without lead times—a vital factor for time-sensitive defense projects.

The four classes of TDI’s turbojet engines now available are:

  • TDI-J45: 30 lb thrust
  • TDI-J5: 75 lb thrust
  • TDI-J7: 100 lb thrust
  • TDI-J85: 200 lb thrust
Kratos TDI's Available Engines

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8bf86f0f-60b1-449f-a30b-1a80222276d1

“We understand the importance of rapidly fielding cost-effective solutions in today’s fast-paced defense environment,” said Steve Fendley, President of Kratos Unmanned Systems Division. “With the large number of programs and technology efforts underway in the affordable weapons classes, by building ahead and having these affordable and high-performance engines stocked on our shelves in Michigan, we enable rapid evaluation, test, integration, and ultimately, all up round delivery without the traditional front end lead-time delays.”

Each TDI engine is 100% USA-designed, sourced, and manufactured, ensuring both quality and security. TDI has developed and refined turbine engine technologies for military applications in Michigan since 1983—providing unique features in support of low-cost, high-production, expendable turbojet engine applications, such as small cruise missiles and other Unmanned Aerial Vehicles (UAVs). With the engineering, manufacturing, and system integration employees in the Oxford, Michigan facility, TDI’s subject matter experts leverage Michigan’s deep automotive expertise and apply it to the defense sector and have experience that encompasses all aspects of this turbine engine class, from clean-sheet design, through performance testing, vehicle integration, flight testing, and production manufacturing.

TDI

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/68ef20cd-8410-48b4-8098-64d4d8e5ba5b

To learn more about TDI’s turbojet engines and their immediate availability, visit our booth at the upcoming Air Force Association’s Air, Space & Cyber Conference or www.tdi-engines.com.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 31, 2023, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Burghoff
claire.burghoff@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Source: Kratos Defense & Security Solutions, Inc.

Release – Kelly Announces Chief Financial Officer Transition

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on KELYA

TROY, Mich., Sept. 12, 2024 (GLOBE NEWSWIRE) — Kelly (Nasdaq: KELYA, KELYB), a leading global specialty talent solutions provider, today announced that Troy R. Anderson has been named executive vice president and chief financial officer designate, effective October 14, 2024. Following an orderly transition of responsibilities, Anderson will succeed Olivier Thirot, executive vice president and chief financial officer, who on July 8, 2024, informed Kelly of his intention to retire as an officer of the Company. Upon completion of the transition, Thirot will serve as a strategic advisor to the Company.

“I am pleased to welcome Troy to Kelly as the Company’s next chief financial officer. His experience successfully executing business transformations, track record of accelerating profitable growth, and passion for developing and leading high-performing teams align exceptionally well to Kelly’s goals as we accelerate forward on our specialty journey into a new era of growth,” said Peter Quigley, president and chief executive officer. “I am also grateful to Olivier for his distinguished service to Kelly. His leadership has helped transform Kelly into a more efficient, profitable enterprise with the financial discipline and flexibility to drive long-term value creation.”

“On behalf of Kelly’s board of directors, I extend our appreciation to Olivier for his significant contributions to the Company as he prepares for an exciting new chapter,” said Terrence Larkin, chairman of Kelly’s board of directors. “I would also like to thank the members of the compensation and talent management committee for leading an exhaustive search process and identifying a candidate of Troy’s caliber to serve as Kelly’s next chief financial officer. I am confident he will serve as an excellent addition to Kelly’s senior leadership team and help build upon the progress Kelly has achieved on its journey to accelerate profitable growth and reward its shareholders.”

Anderson brings to Kelly more than 30 years of progressive experience in accounting, financial planning and analysis, external reporting, investor relations, expense management, and financial strategy. Most recently, he served as executive vice president and chief financial officer of Universal Technical Institute, Inc. (NYSE: UTI), a leading provider of education programs to prepare the workforce in transportation, skilled trades, energy, and healthcare. There, he was a key part of developing and executing a growth, diversification, and optimization strategy which resulted in revenue more than doubling, and profitability and market cap increasing significantly more during his tenure. Prior to joining Universal Technical Institute, Inc., he served as vice president, global finance and corporate controller for Conduent, Inc., a business process services company.

About Kelly®

Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect more than 500,000 people with work every year. Our suite of outsourcing and consulting services ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2023 was $4.8 billion. Learn more at kellyservices.com.

Forward-Looking Statements

This release contains statements that are forward looking in nature and, accordingly, are subject to risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Kelly’s financial expectations, are forward-looking statements. Factors that could cause actual results to differ materially from those contained in this release include, but are not limited to, (i) changing market and economic conditions, (ii) disruption in the labor market and weakened demand for human capital resulting from technological advances, loss of large corporate customers and government contractor requirements, (iii) the impact of laws and regulations (including federal, state and international tax laws), (iv) unexpected changes in claim trends on workers’ compensation, unemployment, disability and medical benefit plans, (v) litigation and other legal liabilities (including tax liabilities) in excess of our estimates, (vi) our ability to achieve our business’s anticipated growth strategies, (vi) our future business development, results of operations and financial condition, (vii) damage to our brands, (viii) dependency on third parties for the execution of critical functions, (ix) conducting business in foreign countries, including foreign currency fluctuations, (x) availability of temporary workers with appropriate skills required by customers, (xi) cyberattacks or other breaches of network or information technology security, and (xii) other risks, uncertainties and factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release and we undertake no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations.

KLYA-FIN

ANALYST CONTACT:
Scott Thomas
(248) 251-7264
scott.thomas@kellyservices.com		                    MEDIA CONTACT:
Jerry Grider
(260) 444-9654
jerry.grider@kellyservices.com

MustGrow Biologics Corp. (MGROF) – Onto the East Coast

Posted on by cpereira@noblefcm.com


Thursday, September 12, 2024

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Another Approval. Following the approval from the state of Arizona late last month, MustGrow announced receipt from the Florida Department of Agriculture and Consumer Services (FDACS) for the registration approval of its TerraSante product. Florida now becomes the sixth state to approve the Company’s product alongside Arizona, Idaho, California, Oregon, and Washington.

Florida Market. The state consists of around 47,300 farms which utilized 9.7 million acres, 5,000 farms of which had sales exceeding $100,000 according to the FDACS. Florida ranked first in 2022 in value of the production of bell peppers, Valencia oranges, grapefruit, sugarcane, fresh market tomatoes, and watermelons. The average farm size in the state is around 205 acres. The state adds plenty of opportunity to MustGrow’s expanding pipeline and we expect more states to be added in the future.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

MAIA Biotechnology (MAIA) – New THIO Data Shows Improved Survival and Meets Trial Goals

Posted on by cpereira@noblefcm.com


Thursday, September 12, 2024

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Data Announced For Additional Patients. MAIA announced new interim data from its Phase 2 THIO-101 open-label trial testing the combination of THIO and Libtayo in non-small cell lung cancer. The new data shows that as of August 1, 2024, 16 patients had passed the 12-month survival point with reported median survival of 10.2 months. This greatly exceeds published data for comparable patients with survival of 5.8 months.

THIO-101 Treated Third-Line Patients With Advanced Disease. Patients in the trial had advanced non-small cell lung cancer (NSCLC) and were treated with the combination of THIO and cemiplimab (Libtayo, an anti-PD-1 checkpoint inhibitor from Regeneron) after failing 2 or more standard-of-care therapy regimens. Patients received 3-week cycles of THIO 60 mg administered on days 1, 2 and 3 (180 mg total), rest on day 4, and cemiplimab 350mg administered on day 5. Patients on treatment for 12-months have received up to 21 cycles.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Bowlero (BOWL) – Floating Increased M&A Activity

Posted on by cpereira@noblefcm.com


Thursday, September 12, 2024

Bowlero Corp. is the worldwide leader in bowling entertainment, media, and events. With more than 300 bowling centers across North America, Bowlero Corp. serves more than 26 million guests each year through a family of brands that includes Bowlero, Bowlmor Lanes, and AMF. In 2019, Bowlero Corp. acquired the Professional Bowlers Association, the major league of bowling, which boasts thousands of members and millions of fans across the globe. For more information on Bowlero Corp., please visit BowleroCorp.com.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q4 results. Q4 revenues exceeded our expectations, $283.9 million (up a strong 18.6% y-o-y) versus our $270.0 million estimate, driven by strong 6.9% growth in same store revenues. Adj. EBITDA was $83.4 million, roughly in line with our $86.5 million estimate.

Resilient against economic headwinds. Management indicated that its business caters to a high end consumer that appears to be resilient to the economy. It plans to roll out high end food items and focus on its event business as a key revenue growth driver in fiscal 2025. Event business is currently $275 million and is expected to exceed $300 million in fiscal 2025.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Federal Reserve Expected to Deliver Quarter-Point Rate Cut Amid Mixed Inflation Data

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– The Fed is likely to cut interest rates by a quarter of a percentage point at its September meeting.
– Mixed inflation data and concerns about the labor market are driving the Fed’s cautious approach
– Traders now expect a year-end policy rate of 4.25%-4.50%, reflecting expectations for further reductions.

The U.S. Federal Reserve is expected to cut interest rates by a quarter of a percentage point at its upcoming September 17-18 policy meeting, marking the beginning of long-anticipated rate reductions. This move comes as the Fed aims to balance reducing inflationary pressures without triggering a recession. Although inflation is still above the Fed’s target, the latest data has provided enough room for the central bank to begin easing its monetary stance.

Wednesday’s release of the Consumer Price Index (CPI) showed a 2.5% increase in August compared to the previous year, down from the 2.9% recorded in July. Core inflation, which excludes volatile food and energy prices, remained steady at 3.2%, with shelter costs unexpectedly accelerating. These mixed signals have complicated the Fed’s decision-making process, with officials choosing a more conservative approach to rate cuts rather than aggressive reductions.

Peter Cardillo, chief market economist at Spartan Capital Securities, noted that the steady core inflation figures signal ongoing concerns. “This report shows core inflation is still a question mark,” Cardillo said, adding that this likely confirms a quarter-percentage-point rate cut from the Fed.

Since July of last year, the Fed has kept interest rates within a range of 5.25% to 5.50%, seeking to curb inflation while preventing significant harm to the labor market. Despite some progress, the Fed’s efforts to bring inflation down to its 2% target have been slower than anticipated. However, Fed officials have indicated that they wish to avoid overcorrecting and stifling the economy, particularly given recent indications that the labor market is cooling.

The latest employment data showed that U.S. hiring has slowed in recent months, but with the unemployment rate ticking down to 4.2% in August, there is no immediate need for the Fed to take drastic action. Instead, a cautious quarter-point reduction appears to be the favored course of action, aimed at offering support to the economy while still maintaining pressure on inflation.

Economist Thomas Simons of Jefferies pointed out that while inflation has not reaccelerated, the latest data offers fewer signs of continued disinflation compared to previous months. This has led traders to adjust their rate expectations, now anticipating a year-end policy rate of 4.25%-4.50%. This suggests that markets are pricing in further rate cuts, including the possibility of a half-percentage-point reduction before the end of the year.

The Fed’s decision next week will be closely watched by investors, economists, and policymakers alike. While a quarter-point cut is widely expected, the central bank’s updated projections for the path of interest rates will offer further insights into how aggressively the Fed plans to ease monetary policy in the coming months. With inflation data continuing to send mixed signals, the Fed’s strategy of gradual rate cuts reflects a desire to keep the economy stable while addressing price pressures.

As traders adjust their positions ahead of the Fed’s meeting, the focus will remain on key economic indicators like inflation and employment. Any unexpected shifts in these metrics could lead to adjustments in market expectations, but for now, the consensus points to a slow and cautious path toward lower interest rates.

Gevo Expands Low-Carbon Portfolio with $210 Million Acquisition of Red Trail Energy Assets

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Gevo to acquire Red Trail Energy’s ethanol production and carbon sequestration assets for $210 million.
– The acquisition accelerates Gevo’s sustainable aviation fuel (SAF) initiatives and carbon abatement strategies.
– The deal is expected to generate positive EBITDA for Gevo by 2025.

Gevo, Inc. has announced a major $210 million acquisition of Red Trail Energy’s ethanol production and carbon sequestration (CCS) assets, positioning the company as a key player in the energy sector’s shift towards sustainability. This move is aligned with Gevo’s mission to produce sustainable aviation fuel (SAF), motor fuels, and chemicals with a net-zero carbon footprint.

The acquisition includes a 65-million-gallon-per-year ethanol production facility and a CCS site that sequesters 160,000 metric tons of carbon annually, with the potential to increase that capacity to 1 million metric tons. The integration of Red Trail’s assets will support Gevo’s existing projects, including its Net-Zero 1 SAF plant in South Dakota, which aims to produce low-carbon fuel while reducing overall greenhouse gas emissions.

This acquisition enhances Gevo’s ability to produce low-carbon ethanol and expand its SAF platform, catering to both the U.S. and Canadian markets. The ethanol produced at the Red Trail site is already distributed across North America, including low-carbon demand markets such as Oregon, Washington, British Columbia, and Alberta. The deal further strengthens Gevo’s ability to contribute to energy decarbonization while adding significant economic value to rural communities.

The energy sector is seeing a shift towards renewable energy sources, and carbon sequestration has become a critical part of the conversation. The Red Trail CCS site, which captures and stores carbon underground, is one of the few operating CCS sites in the U.S. With this acquisition, Gevo aims to scale its carbon capture capabilities, addressing the urgent need for technologies that reduce atmospheric carbon levels while driving energy production.

Gevo’s CEO, Dr. Patrick Gruber, expressed the strategic importance of the acquisition, stating that it accelerates Gevo’s goal of becoming self-sustaining and profitable ahead of its Net-Zero 1 project. The acquisition also helps mitigate risks associated with carbon sequestration for the company’s projects, providing a blueprint for future SAF and carbon abatement initiatives.

From an operational standpoint, Gevo plans to retain the approximately 50 employees currently managing the Red Trail facilities, ensuring continuity and leveraging their expertise. The company also intends to optimize the facility through combined heat and power, further reducing carbon intensity and increasing annual carbon sequestration capabilities. This approach not only improves the efficiency of ethanol production but also enables future expansion into net-zero fuel and chemical production.

The energy sector, particularly in the realm of renewable fuels, is rapidly evolving. Gevo’s acquisition of Red Trail’s assets is a key step in positioning itself at the forefront of the industry’s low-carbon future. The deal is expected to generate positive EBITDA by 2025, a significant milestone for the company, and demonstrates its commitment to driving innovation in the renewable energy space.

As the transaction is expected to close by the first quarter of 2025, pending regulatory approval, it underscores the growing importance of sustainable energy solutions in addressing global climate change, U.S. energy security, and economic growth in rural areas.

Release – Lifeway Foods® Announces New Kefir Distribution in South Africa

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on LWAY

MORTON GROVE, Ill., Sept. 11, 2024 /PRNewswire/ — Lifeway Foods, Inc. (Nasdaq: LWAY) (“Lifeway” or “the Company”), a leading U.S. manufacturer of kefir and fermented probiotic products, announced today the brand’s first expansion of kefir distribution in the South African market. The offering of Lifeway Kefir and ProBugs, exported from the United States, is currently shipping and available on shelves now. The retailers will be a mix of independent and health food stores, along with limited initial placements at established chains such as Pick n Pay and Shoprite.

“We are excited to introduce the U.S. kefir leader to consumers in South Africa,” said Lifeway President and CEO Julie Smolyansky. “Lifeway is taking a thoughtful approach to global expansion and seeking out markets that are primed for success and cann be accessed without major capital investment. The trends around cultured dairy drinkables have never been better, and I look forward to strategically building the Lifeway business worldwide.”

According to Global Market Insights, the global kefir market is projected to grow at a CAGR of over 6.3% and reach $4.9 billion USD by 2032.

About Lifeway Foods, Inc.
Lifeway Foods, Inc., which has been recognized as one of Forbes’ Best Small Companies, is America’s leading supplier of the probiotic, fermented beverage known as kefir. In addition to its line of drinkable kefir, the company also produces a variety of cheeses and a ProBugs line for kids. Lifeway’s tart and tangy fermented dairy products are now sold in the United States, Mexico, Ireland, South Africa and France. Learn how Lifeway is good for more than just you at lifewayfoods.com.

Forward-Looking Statements

This release (and oral statements made regarding the subjects of this release) contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position, business strategy and objectives. These statements use words, and variations of words, such as “continue,” “build,” “future,” “increase,” “drive,” “believe,” “look,” “ahead,” “confident,” “deliver,” “outlook,” “expect,” and “predict.” Other examples of forward-looking statements may include, but are not limited to, (i) statements of Company plans and objectives, including the introduction of new products, or estimates or predictions of actions by customers or suppliers, (ii) statements of future economic performance, and (III) statements of assumptions underlying other statements and statements about Lifeway or its business. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from Lifeway’s expectations and projections. These risks, uncertainties, and other factors include: price competition; the decisions of customers or consumers; the actions of competitors; changes in the pricing of commodities; the effects of government regulation; possible delays in the introduction of new products; and customer acceptance of products and services. A further list and description of these risks, uncertainties, and other factors can be found in Lifeway’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s subsequent filings with the SEC. Copies of these filings are available online at https://www.sec.gov, http://lifewaykefir.com/investor-relations/, or on request from Lifeway. Information in this release is as of the dates and time periods indicated herein, and Lifeway does not undertake to update any of the information contained in these materials, except as required by law. Accordingly, YOU SHOULD NOT RELY ON THE ACCURACY OF ANY OF THE STATEMENTS OR OTHER INFORMATION CONTAINED IN ANY ARCHIVED PRESS RELEASE

Media:
Derek Miller 
Vice President of Communications, Lifeway Foods
Email: derekm@lifeway.net 

General inquiries:
Lifeway Foods, Inc.
Phone: 847-967-1010
Email: info@lifeway.net